Apalutamide is a 2nd generation androgen receptor antagonist approved by the Food and Drug Association in 2018. As a class of drugs, 2nd generation androgen receptor antagonists improve overall survival in prostate cancer patients. Apalutamide is a strong potential alternative candidate.